REGENERON PHARMACEUTICALS, INC. — Revenue by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2dc9492b-8afa-424a-a63e-3c4cc18bafa8/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $14.3B | 2025-01-01 – 2025-12-31 | evidence 0000872589-26-000008 |
| FY 2024 | $14.2B | 2024-01-01 – 2024-12-31 | evidence 0001804220-25-000011 |
| FY 2023 | $13.1B | 2023-01-01 – 2023-12-31 | evidence 0001804220-24-000009 |
| FY 2022 | $12.2B | 2022-01-01 – 2022-12-31 | evidence 0001804220-23-000008 |
| FY 2021 | $16.1B | 2021-01-01 – 2021-12-31 | evidence 0001804220-22-000007 |
| FY 2020 | $8.5B | 2020-01-01 – 2020-12-31 | evidence 0001804220-21-000008 |
| FY 2019 | $6.6B | 2019-01-01 – 2019-12-31 | evidence 0001804220-21-000008 |
| FY 2018 | $5.1B | 2018-01-01 – 2018-12-31 | evidence 0001804220-21-000008 |
| FY 2017 | $5.9B | 2017-01-01 – 2017-12-31 | evidence 0001532176-19-000009 |
| FY 2016 | $4.9B | 2016-01-01 – 2016-12-31 | evidence 0001532176-19-000009 |
| FY 2015 | $2.7B | 2015-01-01 – 2015-12-31 | evidence 0001532176-16-000045 |
| FY 2014 | $1.8B | 2014-01-01 – 2014-12-31 | evidence 0001532176-15-000008 |
| FY 2013 | $1.4B | 2013-01-01 – 2013-12-31 | evidence 0001532176-14-000008 |
| FY 2012 | $858.1M | 2012-01-01 – 2012-12-31 | evidence 0001532176-13-000004 |
| FY 2011 | $445.8M | 2011-01-01 – 2011-12-31 | evidence 0001206774-12-000709 |
| FY 2010 | $459.1M | 2010-01-01 – 2010-12-31 | evidence 0001206774-11-000263 |
| FY 2009 | $379.3M | 2009-01-01 – 2009-12-31 | evidence 0001206774-11-000263 |
| FY 2008 | $238.5M | 2008-01-01 – 2008-12-31 | evidence 0001206774-11-000263 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
REGENERON PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income